Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 11/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31745524 | 0.87 | TNK2 (0.36) | TNK2GRM2ALDH1A1BTK | |
| SCHEMBL31745554 | 0.83 | TNK2 (0.37) | TNK2BTKADAMTS4 | |
| SCHEMBL31745483 | 0.79 | MAPT (0.36) | TNK2GRM2ALDH1A1KDM4EBTK | |
| SCHEMBL31745488 | 0.76 | TNK2 (0.39) | TNK2BTK | |
| SCHEMBL31745562 | 0.70 | KDM4E (0.37) | TNK2GRM2ALDH1A1KDM4ERXFP1 | |
| SCHEMBL31360456 | 0.69 | PRF1 (0.35) | ALDH1A1KDM4ERXFP1GAASMN1; SMN2 | |
| SCHEMBL31745510 | 0.67 | KDM4E (0.35) | TNK2KDM4EBTKRXFP1HTT | |
| SCHEMBL31745440 | 0.67 | PRF1 (0.35) | TNK2GRM2ALDH1A1KDM4ERXFP1 | |
| SCHEMBL31745553 | 0.67 | GRM2 (0.31) | GRM2KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL25715990 | 0.66 | TNK2 (0.51) | TNK2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382297-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | INSILICO MEDICINE IP LTD (HK) | 2025-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382297-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | FGFR3, FGFR2, FGFR1 | TNK2 452/4885GRM2 1031/4885ALDH1A1 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.